Acute Cellular Rejection: Impact of Donor-Specific Antibodies and C4d

Background Mixed rejection in kidney transplantation consists of histologic and/or serological evidence of both cellular and humoral components. As it is not confined to a distinct category in the Banff classification, how to best manage these patients is not clear. The aim of this study was to dete...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation 2014-02, Vol.97 (4), p.np-np
Hauptverfasser: Willicombe, Michelle, Roufosse, Candice, Brookes, Paul, McLean, Adam G, Galliford, Jack, Cairns, Tom, Cook, Terry H, Taube, David
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page np
container_issue 4
container_start_page np
container_title Transplantation
container_volume 97
creator Willicombe, Michelle
Roufosse, Candice
Brookes, Paul
McLean, Adam G
Galliford, Jack
Cairns, Tom
Cook, Terry H
Taube, David
description Background Mixed rejection in kidney transplantation consists of histologic and/or serological evidence of both cellular and humoral components. As it is not confined to a distinct category in the Banff classification, how to best manage these patients is not clear. The aim of this study was to determine the incidence and outcome of morphological T-cell-mediated rejection (TCMR) with a humoral component, defined as the presence of either DSA or C4d, compared with the outcome of pure TCMR. Methods We retrospectively studied 922 consecutive renal transplant recipients and analyzed patients with TCMR according to the evidence of a humoral component. Results A total of 147 cases of morphological TCMR were analyzed. Of these, 92 (62.6%) had "pure" TCMR and 55 (37.4%) had "mixed" TCMR on the index biopsy. On univariant analysis, diffuse C4d (odds ratio [OR]=10.9, 95% confidence interval [CI]=1.8-66.9, P=0.01) and DSA positivity at the time of index biopsy (OR=2.8, 95% CI=1.2-6.6, P=0.02) were associated with allograft loss, whereas arteritis (OR=0.5, 95% CI=0.2-1.2, P=0.11) and glomerulitis (OR=0.9, 95% CI=0.4-2.1, P=0.8) were not. Arteritis was associated with subsequent antibody-mediated rejection (OR=4.9, 95% CI=1.1-20.8, P=0.03), and glomerulitis was associated with the development of transplant glomerulopathy (OR=10.7, 95% CI=3.1-37.1,P
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1635020731</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1635020731</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_16350207313</originalsourceid><addsrcrecordid>eNqVzb0KwjAUQOEMCtafd7ijS-HGtAbcSq3oqu4lpreQkia1Sd5fB1_A6SwfnAXLEAuecyHkiq1DGBCxFFJmrKl0igQ1WZusmuFOA-lovDvBbZyUjuB7OHvn5_wxkTa90VC5aF6-MxRAuQ7qotuyZa9soN2vG7a_NM_6mk-zfycKsR1N0N-HcuRTaPlRlHhAKbj4g34A9YM9FA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1635020731</pqid></control><display><type>article</type><title>Acute Cellular Rejection: Impact of Donor-Specific Antibodies and C4d</title><source>Journals@Ovid Ovid Autoload</source><creator>Willicombe, Michelle ; Roufosse, Candice ; Brookes, Paul ; McLean, Adam G ; Galliford, Jack ; Cairns, Tom ; Cook, Terry H ; Taube, David</creator><creatorcontrib>Willicombe, Michelle ; Roufosse, Candice ; Brookes, Paul ; McLean, Adam G ; Galliford, Jack ; Cairns, Tom ; Cook, Terry H ; Taube, David</creatorcontrib><description>Background Mixed rejection in kidney transplantation consists of histologic and/or serological evidence of both cellular and humoral components. As it is not confined to a distinct category in the Banff classification, how to best manage these patients is not clear. The aim of this study was to determine the incidence and outcome of morphological T-cell-mediated rejection (TCMR) with a humoral component, defined as the presence of either DSA or C4d, compared with the outcome of pure TCMR. Methods We retrospectively studied 922 consecutive renal transplant recipients and analyzed patients with TCMR according to the evidence of a humoral component. Results A total of 147 cases of morphological TCMR were analyzed. Of these, 92 (62.6%) had "pure" TCMR and 55 (37.4%) had "mixed" TCMR on the index biopsy. On univariant analysis, diffuse C4d (odds ratio [OR]=10.9, 95% confidence interval [CI]=1.8-66.9, P=0.01) and DSA positivity at the time of index biopsy (OR=2.8, 95% CI=1.2-6.6, P=0.02) were associated with allograft loss, whereas arteritis (OR=0.5, 95% CI=0.2-1.2, P=0.11) and glomerulitis (OR=0.9, 95% CI=0.4-2.1, P=0.8) were not. Arteritis was associated with subsequent antibody-mediated rejection (OR=4.9, 95% CI=1.1-20.8, P=0.03), and glomerulitis was associated with the development of transplant glomerulopathy (OR=10.7, 95% CI=3.1-37.1,P&lt;0.01). On the multivariate analysis, only patients with C4d and DSA were at risk of graft failure (OR=4.9, 95% CI=2.0-12.0, P&lt;0.01) in the medium term. Conclusion TCMR with a humoral component has a worse prognosis when compared with pure TCMR. As such, it is important to test for alloantibody in cases of morphological TCMR to optimize patient management. Such cases might benefit from more aggressive immunotherapy.</description><identifier>ISSN: 0041-1337</identifier><language>eng</language><ispartof>Transplantation, 2014-02, Vol.97 (4), p.np-np</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Willicombe, Michelle</creatorcontrib><creatorcontrib>Roufosse, Candice</creatorcontrib><creatorcontrib>Brookes, Paul</creatorcontrib><creatorcontrib>McLean, Adam G</creatorcontrib><creatorcontrib>Galliford, Jack</creatorcontrib><creatorcontrib>Cairns, Tom</creatorcontrib><creatorcontrib>Cook, Terry H</creatorcontrib><creatorcontrib>Taube, David</creatorcontrib><title>Acute Cellular Rejection: Impact of Donor-Specific Antibodies and C4d</title><title>Transplantation</title><description>Background Mixed rejection in kidney transplantation consists of histologic and/or serological evidence of both cellular and humoral components. As it is not confined to a distinct category in the Banff classification, how to best manage these patients is not clear. The aim of this study was to determine the incidence and outcome of morphological T-cell-mediated rejection (TCMR) with a humoral component, defined as the presence of either DSA or C4d, compared with the outcome of pure TCMR. Methods We retrospectively studied 922 consecutive renal transplant recipients and analyzed patients with TCMR according to the evidence of a humoral component. Results A total of 147 cases of morphological TCMR were analyzed. Of these, 92 (62.6%) had "pure" TCMR and 55 (37.4%) had "mixed" TCMR on the index biopsy. On univariant analysis, diffuse C4d (odds ratio [OR]=10.9, 95% confidence interval [CI]=1.8-66.9, P=0.01) and DSA positivity at the time of index biopsy (OR=2.8, 95% CI=1.2-6.6, P=0.02) were associated with allograft loss, whereas arteritis (OR=0.5, 95% CI=0.2-1.2, P=0.11) and glomerulitis (OR=0.9, 95% CI=0.4-2.1, P=0.8) were not. Arteritis was associated with subsequent antibody-mediated rejection (OR=4.9, 95% CI=1.1-20.8, P=0.03), and glomerulitis was associated with the development of transplant glomerulopathy (OR=10.7, 95% CI=3.1-37.1,P&lt;0.01). On the multivariate analysis, only patients with C4d and DSA were at risk of graft failure (OR=4.9, 95% CI=2.0-12.0, P&lt;0.01) in the medium term. Conclusion TCMR with a humoral component has a worse prognosis when compared with pure TCMR. As such, it is important to test for alloantibody in cases of morphological TCMR to optimize patient management. Such cases might benefit from more aggressive immunotherapy.</description><issn>0041-1337</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqVzb0KwjAUQOEMCtafd7ijS-HGtAbcSq3oqu4lpreQkia1Sd5fB1_A6SwfnAXLEAuecyHkiq1DGBCxFFJmrKl0igQ1WZusmuFOA-lovDvBbZyUjuB7OHvn5_wxkTa90VC5aF6-MxRAuQ7qotuyZa9soN2vG7a_NM_6mk-zfycKsR1N0N-HcuRTaPlRlHhAKbj4g34A9YM9FA</recordid><startdate>20140227</startdate><enddate>20140227</enddate><creator>Willicombe, Michelle</creator><creator>Roufosse, Candice</creator><creator>Brookes, Paul</creator><creator>McLean, Adam G</creator><creator>Galliford, Jack</creator><creator>Cairns, Tom</creator><creator>Cook, Terry H</creator><creator>Taube, David</creator><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20140227</creationdate><title>Acute Cellular Rejection: Impact of Donor-Specific Antibodies and C4d</title><author>Willicombe, Michelle ; Roufosse, Candice ; Brookes, Paul ; McLean, Adam G ; Galliford, Jack ; Cairns, Tom ; Cook, Terry H ; Taube, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_16350207313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Willicombe, Michelle</creatorcontrib><creatorcontrib>Roufosse, Candice</creatorcontrib><creatorcontrib>Brookes, Paul</creatorcontrib><creatorcontrib>McLean, Adam G</creatorcontrib><creatorcontrib>Galliford, Jack</creatorcontrib><creatorcontrib>Cairns, Tom</creatorcontrib><creatorcontrib>Cook, Terry H</creatorcontrib><creatorcontrib>Taube, David</creatorcontrib><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Willicombe, Michelle</au><au>Roufosse, Candice</au><au>Brookes, Paul</au><au>McLean, Adam G</au><au>Galliford, Jack</au><au>Cairns, Tom</au><au>Cook, Terry H</au><au>Taube, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute Cellular Rejection: Impact of Donor-Specific Antibodies and C4d</atitle><jtitle>Transplantation</jtitle><date>2014-02-27</date><risdate>2014</risdate><volume>97</volume><issue>4</issue><spage>np</spage><epage>np</epage><pages>np-np</pages><issn>0041-1337</issn><abstract>Background Mixed rejection in kidney transplantation consists of histologic and/or serological evidence of both cellular and humoral components. As it is not confined to a distinct category in the Banff classification, how to best manage these patients is not clear. The aim of this study was to determine the incidence and outcome of morphological T-cell-mediated rejection (TCMR) with a humoral component, defined as the presence of either DSA or C4d, compared with the outcome of pure TCMR. Methods We retrospectively studied 922 consecutive renal transplant recipients and analyzed patients with TCMR according to the evidence of a humoral component. Results A total of 147 cases of morphological TCMR were analyzed. Of these, 92 (62.6%) had "pure" TCMR and 55 (37.4%) had "mixed" TCMR on the index biopsy. On univariant analysis, diffuse C4d (odds ratio [OR]=10.9, 95% confidence interval [CI]=1.8-66.9, P=0.01) and DSA positivity at the time of index biopsy (OR=2.8, 95% CI=1.2-6.6, P=0.02) were associated with allograft loss, whereas arteritis (OR=0.5, 95% CI=0.2-1.2, P=0.11) and glomerulitis (OR=0.9, 95% CI=0.4-2.1, P=0.8) were not. Arteritis was associated with subsequent antibody-mediated rejection (OR=4.9, 95% CI=1.1-20.8, P=0.03), and glomerulitis was associated with the development of transplant glomerulopathy (OR=10.7, 95% CI=3.1-37.1,P&lt;0.01). On the multivariate analysis, only patients with C4d and DSA were at risk of graft failure (OR=4.9, 95% CI=2.0-12.0, P&lt;0.01) in the medium term. Conclusion TCMR with a humoral component has a worse prognosis when compared with pure TCMR. As such, it is important to test for alloantibody in cases of morphological TCMR to optimize patient management. Such cases might benefit from more aggressive immunotherapy.</abstract></addata></record>
fulltext fulltext
identifier ISSN: 0041-1337
ispartof Transplantation, 2014-02, Vol.97 (4), p.np-np
issn 0041-1337
language eng
recordid cdi_proquest_miscellaneous_1635020731
source Journals@Ovid Ovid Autoload
title Acute Cellular Rejection: Impact of Donor-Specific Antibodies and C4d
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T08%3A25%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20Cellular%20Rejection:%20Impact%20of%20Donor-Specific%20Antibodies%20and%20C4d&rft.jtitle=Transplantation&rft.au=Willicombe,%20Michelle&rft.date=2014-02-27&rft.volume=97&rft.issue=4&rft.spage=np&rft.epage=np&rft.pages=np-np&rft.issn=0041-1337&rft_id=info:doi/&rft_dat=%3Cproquest%3E1635020731%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1635020731&rft_id=info:pmid/&rfr_iscdi=true